Cancer

Showing 15 posts of 1067 posts found.

000000000000000_tttt

Researchers modify T-cells to identify and target multiple sites on leukaemia cells

April 1, 2020
Research and Development Cancer, Cancers, children cancer, leukaemia

Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …

astrazeneca_building_white

FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer

March 30, 2020
Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma

AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …

Roche shows improved survival rates in new treatment for untreated acute myeloid leukaemia

March 24, 2020
Manufacturing and Production Cancer, Roche, acute myeloid leukamia

Roche has announced that its clinical trials for Venclexta/Venclyzto combination with azacitidine have met its primary endpoints of overall survival …

lung_cancer_on_chest_x-ray

AI may help predict patient response to non-small cell lung cancer therapies

March 23, 2020
Medical Communications, Sales and Marketing Cancer, Lesions, cancer treatment, tumour treatment

Researchers have used artificial intelligence to train algorithms to predict tumour sensitivity to systemic cancer therapies. Radiologists previously determined if …

science_nhmrc-grant-annoucement_180824_-_pic_1

New findings on influenza could help improve cancer treatments

March 20, 2020
Manufacturing and Production, Medical Communications Cancer, cancer treatments, flu, flu treatments, influenza

A new study into how the body fights influenza could help improve cancer immunotherapies. Researchers at the Fox Chase Cancer …

astrazeneca_building_white

Success and failure at Phase 3 for AstraZeneca’s Imfinzi combos in first-line small cell lung cancer

March 17, 2020
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, pharma

AstraZeneca has pulled back the curtain on new Phase 3 data for Imfinzi (durvalumab) in the first-line treatment of extensive-stage …

shutterstock_159488225

Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …

merck-keytruda

Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …

shutterstock

Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

March 6, 2020
Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …

az_logo

Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer

March 6, 2020
Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure

New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …

gilead_hq_at_stockley_park_london_2

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma

Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …

6684097669_b859b7ea96_b

E. coli strain in the gut may increase risk of bowel cancer, new study finds

February 28, 2020
Medical Communications Cancer, E. coli, bowel cancer, bowels, cancer research, e coli, oncology

A type of E. coli infection may increase a person’s chance of developing bowel cancer, according to a new study …

celgene_building

NICE recommends Celgene’s Revlimid combo for follicular lymphoma

February 27, 2020
Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …

The Gateway to Local Adoption Series

Latest content